featured
Intravitreal Faricimab Efficacy, Durability, and Safety at 1-Year Follow-up
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
Lancet 2022 Jan 21;[EPub Ahead of Print], CC Wykoff, F Abreu, AP Adamis, K Basu, DA Eichenbaum, Z Haskova, H Lin, A Loewenstein, S Mohan, IA Pearce, T Sakamoto, PG Schlottmann, D Silverman, JK Sun, JA Wells, JR Willis, R TadayoniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.